AI is reengineering drug discovery by speeding up testing and scanning petabytes of data
Why it matters: AI's integration into drug discovery could drastically reduce the time and cost of bringing new medications to patients.
- The Conversation webinar featured experts discussing AI's transformative impact on drug discovery and development.
- AI is reengineering drug discovery by significantly speeding up testing processes.
- AI is capable of scanning petabytes of data, a task impossible for traditional methods, to identify drug candidates more efficiently.
AI is revolutionizing drug discovery by drastically accelerating testing and enabling the analysis of vast datasets, as highlighted in a recent webinar hosted by The Conversation. Experts Jeffrey Skolnick and Benjamin P. Brown discussed how this technology is fundamentally reengineering the process, promising faster identification of potential drug candidates.
